P/E at 29.67 vs Industry's 36.44: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.67 for Dr Reddys Laboratories Ltd represents a discount of approximately 18.5% relative to the sector’s average of 36.44. This valuation gap suggests that the market is pricing in either a subdued growth outlook or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, this discount is analytically significant. It raises the question of whether the stock’s lower valuation is justified by fundamentals or if it presents a valuation anomaly — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a complex performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 12.54%, underperforming the Sensex’s 10.03% fall. The year-to-date return of -9.79% is slightly better than the Sensex’s -12.69%, indicating some recovery in recent months. However, the three-month return of -9.65% is markedly worse than the Sensex’s -3.57%, highlighting a period of intensified weakness. This divergence suggests that while the stock has struggled over the medium term, it has shown relative resilience in the short term, with a 1-month return of -3.81% slightly outperforming the Sensex’s -4.28%. The 1-week and 1-day performances are positive, with gains of 0.51% and 0.12% respectively, compared to the Sensex’s negative 0.67% and positive 0.09%. This pattern of recent modest gains amid a longer-term downtrend — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — merits further technical scrutiny.

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd remains challenging. The stock is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This configuration typically signals a sustained downtrend, with no immediate signs of technical recovery. The fact that the stock has been losing ground for three consecutive days, with a cumulative decline of 1.77%, reinforces the bearish momentum. Trading below the 200-day moving average is often viewed as a critical resistance level, and the stock’s inability to breach this suggests that any short-term rallies may be limited in scope. The current setup contrasts with the modest short-term gains, indicating that the recent uptick may be a temporary relief rather than a trend reversal.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution suggests a sector grappling with uneven performance, possibly due to regulatory pressures, pricing challenges, or pipeline uncertainties. Within this context, Dr Reddys Laboratories Ltd’s underperformance relative to the sector average and its subdued valuation may reflect broader sector headwinds. However, the stock’s relative outperformance in the year-to-date period compared to the Sensex indicates some defensive qualities amid sector volatility — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Reassessment: From Hold to a New Status

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a different grade, reflecting a reassessment of its fundamentals and market position. The previous Mojo Score stood at 30.0, with a mid-cap market capitalisation of ₹95,704.44 crores. The rating change aligns with the stock’s valuation discount and recent performance trends, signalling a shift in the analytical view. This reassessment invites investors to revisit their stance on the stock in light of the evolving data — what is the current rating for Dr Reddys Laboratories Ltd?

Long-Term Performance: Lagging Behind the Sensex

Looking beyond the recent periods, Dr Reddys Laboratories Ltd has underperformed the Sensex over multiple long-term horizons. The 3-year return is -1.54% compared to the Sensex’s 9.68%, while the 5-year return stands at 17.26% against the Sensex’s 26.07%. Over a decade, the stock has delivered 81.93%, significantly trailing the Sensex’s 160.16%. This persistent underperformance over extended periods highlights structural challenges or slower growth relative to the broader market. The data suggests that while the stock has delivered positive absolute returns, it has not kept pace with the market’s broader gains.

Short-Term Price Action: Modest Gains Amid a Downtrend

Despite the longer-term weakness, the stock has shown some resilience in the very short term. The 1-day gain of 0.12% and 1-week gain of 0.51% outpace the Sensex’s 0.09% and -0.67% respectively. However, this comes after a three-day losing streak with a cumulative decline of 1.77%, indicating volatility and uncertainty. The stock opened at ₹1140.5 and has traded around this level, reflecting a consolidation phase. The juxtaposition of short-term gains within a broader downtrend — is this a recovery or a dead-cat bounce? — remains a key question for technical analysts and investors alike.

Collective Data Insights: A Complex Picture

The data for Dr Reddys Laboratories Ltd paints a nuanced picture. The valuation discount to the sector average contrasts with the stock’s underperformance over one and three years. Short-term momentum shows tentative improvement, but the technical setup remains bearish with the stock below all major moving averages. Sector results are mixed, and the recent rating reassessment from Hold reflects these complexities. Investors analysing this stock must weigh the valuation premium against the persistent performance challenges and technical signals — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →